News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Invion.
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health Stocks: Invion demonstrates efficacy, Biotron gets feedback from the FDA
Health & Biotech
Check Up: Imagion and Invion both target breast cancer clinical trials
News
October Winners Column: The ASX returned to growth and coal, steel, hydrogen and tech all benefited
News
Rise and Shine: What you need to know before the ASX opens
News
Closing Bell: Cancer-fighting medtech stock rockets 138% higher as ASX trades flat
News
ASX Small Cap Lunch Wrap: Who’s unearthed hidden secrets this morning?
News
10 at 10: These ASX stocks have returned salute to their shareholders this morning
Health & Biotech
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed
News
Weekly ASX small cap wrap: Who’s cruising ahead this week?
News
10 at 10: These ASX stocks have risen to the skies this morning
News
May Winners Column: Uranium, biotechs and real estate takeover targets put in the hard yards on the ASX
Health & Biotech
Invion led a group of ASX cancer stocks up after promising news
News
ASX Small Cap Lunch Wrap: Biden’s less-generous infrastructure bill is somehow good news for share markets
News
10 at 10: These ASX stocks have made the biggest launch this morning
Health & Biotech
Mesoblast burnt $108m in FY20 waiting on key FDA ruling
Health & Biotech
Health: Amplia really gives a FAK about cancer as phase 1 trial still on track
Health & Biotech
